Tibra Equities Europe Ltd purchased a new stake in Anavex Life Sciences Corp (NASDAQ:AVXL) in the 1st quarter, Holdings Channel reports. The fund purchased 84,445 shares of the biotechnology company’s stock, valued at approximately $258,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Deutsche Bank AG purchased a new stake in Anavex Life Sciences during the 4th quarter worth $28,000. Geode Capital Management LLC boosted its position in Anavex Life Sciences by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 291,948 shares of the biotechnology company’s stock worth $455,000 after purchasing an additional 3,687 shares during the period. Park West Asset Management LLC boosted its position in Anavex Life Sciences by 1.6% during the 4th quarter. Park West Asset Management LLC now owns 3,495,615 shares of the biotechnology company’s stock worth $5,453,000 after purchasing an additional 53,450 shares during the period. Finally, Hikari Power Ltd purchased a new stake in Anavex Life Sciences during the 4th quarter worth $231,000. Institutional investors own 14.12% of the company’s stock.

Shares of Anavex Life Sciences stock opened at $2.75 on Wednesday. The firm has a market cap of $131.99 million, a P/E ratio of -7.05 and a beta of 2.54. Anavex Life Sciences Corp has a twelve month low of $1.25 and a twelve month high of $4.35.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Thursday, February 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). As a group, analysts anticipate that Anavex Life Sciences Corp will post -0.48 earnings per share for the current year.

A number of analysts recently weighed in on the stock. Maxim Group set a $7.00 price target on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research report on Thursday, December 13th. Zacks Investment Research cut shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research report on Monday, April 1st. Finally, Roth Capital set a $10.00 price target on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research report on Friday, February 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $7.40.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/tibra-equities-europe-ltd-purchases-shares-of-84445-anavex-life-sciences-corp-avxl/2952928.html.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.

Recommended Story: QQQ ETF

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp (NASDAQ:AVXL).

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.